ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives $24.00 Average Price Target from Analysts

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) have received an average recommendation of "Moderate Buy" from the seventeen research firms that are covering the firm, MarketBeat.com reports. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $24.00.

A number of equities analysts have recently commented on the stock. HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Needham & Company LLC restated a "buy" rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Guggenheim cut shares of ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their price objective for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. StockNews.com downgraded ACADIA Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, November 14th. Finally, Deutsche Bank Aktiengesellschaft began coverage on ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They set a "hold" rating and a $22.00 target price for the company.

ACADIA Pharmaceuticals Stock Down 1.7 %

ACAD stock traded down $0.34 during midday trading on Friday, hitting $19.95. The company's stock had a trading volume of 1,995,038 shares, compared to its average volume of 2,911,013. The stock's 50-day moving average price is $18.15 and its 200 day moving average price is $16.72. The stock has a market cap of $3.32 billion, a price-to-earnings ratio of 25.58 and a beta of 0.37. ACADIA Pharmaceuticals has a 1 year low of $14.15 and a 1 year high of $26.56.

Institutional Trading of ACADIA Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC lifted its position in ACADIA Pharmaceuticals by 380.3% during the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock valued at $45,576,000 after purchasing an additional 1,966,607 shares during the period. Barclays PLC lifted its holdings in ACADIA Pharmaceuticals by 126.2% during the 3rd quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company's stock worth $4,269,000 after buying an additional 154,854 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of ACADIA Pharmaceuticals during the third quarter worth about $483,000. Burney Co. acquired a new position in ACADIA Pharmaceuticals in the 4th quarter valued at about $6,953,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of ACADIA Pharmaceuticals by 259.0% in the third quarter. BNP Paribas Financial Markets now owns 223,618 shares of the biopharmaceutical company's stock valued at $3,439,000 after acquiring an additional 161,331 shares in the last quarter. Institutional investors own 96.71% of the company's stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.